As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Type of study:
Phase I study
Patients receive veliparib orally (PO) twice daily (BID) on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22.
Dana-Farber Cancer Institute
Contact: Geoffrey Shapiro, MD, PhD: 617-632-4942 firstname.lastname@example.org